Compare BILL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BILL | NAMS |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2019 | 2022 |
| Metric | BILL | NAMS |
|---|---|---|
| Price | $47.88 | $26.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $57.90 | $46.75 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,160,000.00 | $22,503,000.00 |
| Revenue This Year | $14.18 | $17.96 |
| Revenue Next Year | $13.83 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $31.41 | $23.05 |
| 52 Week High | $57.21 | $42.21 |
| Indicator | BILL | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 39.13 |
| Support Level | $46.72 | $25.88 |
| Resistance Level | $49.60 | $37.29 |
| Average True Range (ATR) | 2.04 | 1.13 |
| MACD | -0.45 | 0.17 |
| Stochastic Oscillator | 26.67 | 34.98 |
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.